Implant maker Amedica files for $75M IPO
Salt Lake City-based Amedica filed to raise up to $74.8 million in an IPO, just a week after it raised $13.2 million in a fourth funding round. The maker of ceramic implants for spinal and joint repair said it doesn’t expect its first products to reach the market until next year.
Amedica’s S-1 filing, by the way, is the first I can recall seeing that explicitly lists “healthcare reform” as one of its major risk factors:
We face significant uncertainty in the industry due to government healthcare reform.
Political, economic and regulatory influences are subjecting the healthcare industry to fundamental changes. Reforms under consideration in the United States include mandated basic healthcare benefits, controls on healthcare spending, increases in insurance premiums and increased out-of-pocket requirements for patients, the creation of large group purchasing organizations that aim to reduce the costs of products that their member hospitals consume, and significant modifications to the healthcare delivery system. We anticipate that the U.S. Congress and state legislatures will continue to review and assess alternative healthcare delivery systems and payment methods. Due to uncertainties regarding the ultimate features of reform initiatives and the timing of their enactment and implementation, we cannot predict which, if any, of such reform proposals will be adopted, when they may be adopted or what impact reform initiatives may have on us.
This may be standard boilerplate these days, but like they say on TV, it was new to me.
Check out Amedica’s filing and its press release for more.
Next Story: Khosla’s tips on how save the environment
Previous Story: AdaptiveBlue lets you power up links in your blog
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.